RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Nxera Pharma Co Stock

Nxera Pharma Co Dividend 2024

Nxera Pharma Co Dividend

0 JPY

Nxera Pharma Co Dividend yield

0.15 %

Ticker

4565.T

ISIN

JP3431300007

WKN

A0B7EK

How much dividend does Nxera Pharma Co 2024 pay?

According to the latest status from July 2024, Nxera Pharma Co paid a total of 0 JPY per share in dividends within the last 12 months. With the current Nxera Pharma Co price of 1,620 JPY, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.

0.15 % Dividend Yield=
2.5 JPY Dividend
1,620 JPY Stock Price

Historical Nxera Pharma Co Dividends

A dividend is paid times per year. Last year, the payout months were and .

PaydateDividend
4/27/201510
1

Nxera Pharma Co dividend history and estimates

In 2023, Nxera Pharma Co paid a dividend amounting to 0 JPY. Dividend means that Nxera Pharma Co distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Nxera Pharma Co provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Nxera Pharma Co’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Nxera Pharma Co's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Nxera Pharma Co Dividend History

DateNxera Pharma Co Dividend
20152.5 JPY

Is the Nxera Pharma Co Dividend Safe?

Nxera Pharma Co has been increasing the dividend for 1 years.

Over the past 10 years, Nxera Pharma Co has increased it by an annual 0 %.

Over a five-year period, the distribution increased by 0%.

Analysts expect a Dividend Cut of -100% for the current fiscal year.

Nxera Pharma Co dividend payout ratio

In 2023, Nxera Pharma Co had a payout ratio of 0%. The payout ratio indicates the percentage of the company's profits that Nxera Pharma Co distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Nxera Pharma Co represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Nxera Pharma Co could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Nxera Pharma Co's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Nxera Pharma Co Payout Ratio History

DateNxera Pharma Co Payout ratio
2026e0 %
2025e0 %
2024e0 %
20230 %
20220 %
20210 %
20200 %
20190 %
20180 %
20170 %
20160 %
2015-10.69 %
20140 %
20130 %
20120 %
20110 %
20100 %
20090 %
20080 %
20070 %
20060 %
20050 %
20040 %

Dividend Details

Understanding Nxera Pharma Co's Dividend Distributions

Nxera Pharma Co’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.

Year-to-Year Comparison

Examining Nxera Pharma Co's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.

Impact on Investments

Nxera Pharma Co's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.

Interpreting Dividend Fluctuations

Changes in Nxera Pharma Co’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.

Nxera Pharma Co Aktienanalyse

What does Nxera Pharma Co do?

The Sosei Group Corp. is a Japanese company that operates in the fields of pharmaceutical research and development. It was founded in 1990 as Photonamic GmbH & Co KG in Munich, Germany, before being renamed Sosei Co. Ltd. in 2003. The company is headquartered in Tokyo, Japan, and operates research and development facilities in Japan, the United Kingdom, and Denmark. Sosei is involved in several significant drug development projects and has produced some successful products in the past. Business model: The main focus of the Sosei Group Corp. is the research and development of pharmaceuticals. Its primary business model is to be involved in the entire value chain of drug development, from the discovery and characterization of new drug candidates to clinical development and regulatory approval. In order to attract partners in the pharmaceutical and biotech industry, the company offers its core competencies in drug research and development, including optimizing drug candidates and conducting clinical trials. Partnerships can be structured in the form of strategic alliances, licensing fees, milestone payments, and profit sharing. Divisions: The Sosei Group Corp. divides its activities into three main divisions: 1. Sosei Heptares: The company is a leading player in G-protein-coupled receptor (GPCR) research and development. GPCRs are a class of membrane proteins involved in regulating signal transduction processes and are of significant importance in drug development. Sosei Heptares provides its expertise and technology platform to third parties for developing new drugs targeting GPCR. 2. Sosei R&D: Sosei R&D focuses on the discovery and development of new drug candidates in various therapeutic areas, including inflammation, oncology, pain, respiratory, and mental disorders. The company utilizes its proprietary technology platform, which includes computer-aided design and synthesis optimization, to identify and develop new drugs. 3. Sosei CMC: The Sosei CMC department is responsible for developing customized processes for manufacturing pharmaceuticals. It encompasses all aspects of drug manufacturing, from formulation to manufacturing techniques. The department also works closely with other departments of the company to ensure that the drug products meet the highest quality and safety standards. Products: Sosei has developed and brought to market some successful drugs in the past. These include medications such as: 1. NVA237 (glycopyrronium bromide): An inhalation medicine for the treatment of chronic obstructive pulmonary disease (COPD). 2. QVA149 (indacaterol/glycopyrronium bromide): Another inhalation medicine approved for the treatment of COPD. 3. Sovodakso (GSK-491876): A drug candidate developed in partnership with GlaxoSmithKline (GSK) currently under investigation in phase III clinical trials for the treatment of schizophrenia. 4. Aclidinium bromide: An inhalation medicine for the treatment of COPD, developed in partnership with Almirall. In summary, the Sosei Group Corp. is a leading player in pharmaceutical research and development. The company focuses on developing novel drugs for the treatment of a variety of diseases and works closely with partners in the pharmaceutical and biotech industry. With its extensive knowledge and technological expertise, Sosei is one of the few companies capable of overcoming the challenges in drug development. Nxera Pharma Co is one of the most popular companies on Eulerpool.com.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Frequently Asked Questions about Nxera Pharma Co stock

How much dividend does Nxera Pharma Co pay?

Over the past 12 months, Nxera Pharma Co paid a dividend of 2.5 JPY . This corresponds to a dividend yield of about 0.15 %. For the coming 12 months, Nxera Pharma Co is expected to pay a dividend of 0 JPY.

What is the dividend yield of Nxera Pharma Co?

The current dividend yield of Nxera Pharma Co is 0.15 %.

When does Nxera Pharma Co pay dividends?

Nxera Pharma Co pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Nxera Pharma Co?

Nxera Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Nxera Pharma Co?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Nxera Pharma Co located?

Nxera Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Nxera Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Nxera Pharma Co from 6/24/2015 amounting to 10 JPY, you needed to have the stock in your portfolio before the ex-date on 3/27/2015.

When did Nxera Pharma Co pay the last dividend?

The last dividend was paid out on 6/24/2015.

What was the dividend of Nxera Pharma Co in the year 2023?

In the year 2023, Nxera Pharma Co distributed 0 JPY as dividends.

In which currency does Nxera Pharma Co pay out the dividend?

The dividends of Nxera Pharma Co are distributed in JPY.

Andere Kennzahlen von Nxera Pharma Co

Our stock analysis for Nxera Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Nxera Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.